 "Ocugen-Bharat Biotech Covid vaccine meets main goals in US trial: Report")
(Reuters) -Ocugen Inc said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States, sending shares of the U.S. biotech firm 20% higher in premarket trade.
The vaccine, sold under brand name Covaxin, showed an immune response in individuals who had not received a COVID vaccine previously as well as those vaccinated with mRNA vaccines by Pfizer Inc and Moderna Inc, meeting its main goals, Ocugen said.
The vaccine was also found to be well-tolerated in both sets of participants, the company said.
(Reporting by Leroy Leo in Bengaluru; Editing by Savio D'Souza and Shinjini Ganguli)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app